Moderna Reports Third Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Moderna Reports Third Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
November 4, 2021 8:31 AM EDT
Shares of Moderna (NASDAQ: MRNA) are down more than 13% in pre-open Thursday after the company delivered disappointing Q3 results and guidance.
Moderna reported Q3 EPS of $7.70, a handy miss compared to the analyst estimate of $9.05. Revenue for the quarter came in at $5 billion versus the consensus estimate of $6.21 billion.
Shares were further hit by the... More
November 4, 2021 7:03 AM EDT
Moderna (NASDAQ: MRNA) reported Q3 EPS of $7.70, $1.35 worse than the analyst estimate of $9.05. Revenue for the quarter came in at $5 billion versus the consensus estimate of $6.21 billion.
2021 Updated Financial Framework
For Expected Delivery in Fiscal Year (FY) 2021: Expected to realize product sales for FY 2021 between $15 billion and $18 billion.
Key Variables Impacting FY 2021 Revenues: Fewer doses for delivery in 2021, shifted to early 2022; prioritization of deliveries to low-income countries through COVAX and African Union
Vaccine Dose Deliveries for FY 2021:...
More
